Abstract
Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Brain / drug effects*
-
Brain / metabolism
-
Chromatography, High Pressure Liquid / methods
-
Drug Administration Routes
-
Drug Administration Schedule
-
Hydrogen-Ion Concentration
-
Male
-
Minocycline / administration & dosage*
-
Minocycline / blood
-
Minocycline / cerebrospinal fluid
-
Minocycline / pharmacokinetics
-
Neuroprotective Agents / administration & dosage*
-
Neuroprotective Agents / blood
-
Neuroprotective Agents / cerebrospinal fluid
-
Neuroprotective Agents / pharmacokinetics
-
Rats
-
Rats, Sprague-Dawley
-
Temperature
-
Time Factors
Substances
-
Neuroprotective Agents
-
Minocycline